Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02GLD
|
||||
Former ID |
DIB008204
|
||||
Drug Name |
MF-101
|
||||
Synonyms |
Liquiritigenin; Menerba; DW-700; DW-700); Menopause Formula-101; Estrogen receptor beta agonist (menopausal symptoms), Bionovo; Liquiritigenin (menopausal symptoms), Bionovo
|
||||
Indication | Hepatitis virus infection [ICD9: 573.3; ICD10:K75.9] | Phase 3 | [1] | ||
Company |
Bionovo Inc; Daewon Pharm Co Ltd
|
||||
Structure |
![]() |
Download2D MOL |
|||
Canonical SMILES |
c12c(C(=O)C[C@H](O1)c1ccc(cc1)O)ccc(c2)O
|
||||
CAS Number |
CAS 578-86-9
|
||||
Target and Pathway | |||||
Target(s) | Estrogen receptor beta | Target Info | Antagonist | [2] | |
KEGG Pathway | Estrogen signaling pathway | ||||
Prolactin signaling pathway | |||||
Pathway Interaction Database | Plasma membrane estrogen receptor signaling | ||||
Validated nuclear estrogen receptor beta network | |||||
Validated nuclear estrogen receptor alpha network | |||||
Reactome | Nuclear Receptor transcription pathway | ||||
WikiPathways | SIDS Susceptibility Pathways | ||||
Ovarian Infertility Genes | |||||
Integrated Pancreatic Cancer Pathway | |||||
Nuclear Receptors | |||||
References | |||||
REF 1 | ClinicalTrials.gov (NCT00906308) A Study of MF101 in Postmenopausal Women. U.S. National Institutes of Health. | ||||
REF 2 | MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.